Inflammatory disease biotech Kiniksa Pharmaceuticals sets terms for $126 million IPO

Shutterstock photo

Kiniksa Pharmaceuticals, a clinical-stage biotech developing treatments for autoinflammatory and autoimmune conditions, announced terms for its IPO on Monday.

The Lexington, MA-based company plans to raise $126 million by offering 7 million shares at a price range of $17 to $19. Insiders intend to purchase $50 million (40% of deal size) of the IPO. At the midpoint of the proposed range, Kiniksa Pharmaceuticals would command a fully diluted market value of $905 million and an enterprise value of $683 million.

Kiniksa Pharmaceuticals was founded in 2015 and plans to list on the Nasdaq under the symbol KNSA. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal. It is expected to price during the week of May 21, 2018.

The article Inflammatory disease biotech Kiniksa Pharmaceuticals sets terms for $126 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?